Dr. Thomas Kaley, MD

Claim this profile

Memorial Sloan Kettering Cancer Center

Expert in Brain Tumor

Studies Glioblastoma

15 reported clinical trials

23 drugs studied

Area of expertise

1Brain Tumor

Global Leader

Thomas Kaley, MD has run 12 trials for Brain Tumor. Some of their research focus areas include:

IDH positive

Stage III

Stage II

2Glioblastoma

Thomas Kaley, MD has run 5 trials for Glioblastoma. Some of their research focus areas include:

IDH positive

IDH negative

Affiliated Hospitals

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

Clinical Trials Thomas Kaley, MD is currently running

More about Thomas Kaley, MD

Clinical Trial Related6 years of experience running clinical trials · Led 15 trials as a Principal Investigator · 4 Active Clinical Trials

Treatments Thomas Kaley, MD has experience with

Abemaciclib
Pembrolizumab
Temozolomide
Optune (NovoTTF-100A)
AB-218
MRI Perfusion

Breakdown of trials Thomas Kaley, MD has run

Brain Tumor

Glioblastoma

Meningioma

Relapse

Brain Metastases

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).

What does Thomas Kaley, MD specialize in?

Thomas Kaley, MD focuses on Brain Tumor and Glioblastoma. In particular, much of their work with Brain Tumor has involved IDH positive patients, or patients who are Stage III.

Is Thomas Kaley, MD currently recruiting for clinical trials?

Yes, Thomas Kaley, MD is currently recruiting for 4 clinical trials in New York New York. If you're interested in participating, you should apply.

Are there any treatments that Thomas Kaley, MD has studied deeply?

Yes, Thomas Kaley, MD has studied treatments such as Abemaciclib, Pembrolizumab, Temozolomide.

What is the best way to schedule an appointment with Thomas Kaley, MD?

Apply for one of the trials that Thomas Kaley, MD is conducting.

What is the office address of Thomas Kaley, MD?

The office of Thomas Kaley, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.

Is there any support for travel costs?

The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.

Top trials Thomas Kaley, MD is currently running

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.

1045 Sansome St, Suite 321, San Francisco, CA

hello@withpower.com (415) 900-4227

Directories

Locations

Psychology Related

Treatments

Cities

···

Dr. Thomas Kaley, MD

Memorial Sloan Kettering Cancer Center

Area of expertise

Affiliated Hospitals

Clinical Trials Thomas Kaley, MD is currently running

More about Thomas Kaley, MD

Other Doctors you might be interested in

Frequently asked questions

Personalize Your Experience

Save Your Preferences

Understand How the Site Is Used

Dr. Thomas Kaley, MD

Memorial Sloan Kettering Cancer Center

Area of expertise

Affiliated Hospitals

Clinical Trials Thomas Kaley, MD is currently running

Multiple Targeted Therapies

for Meningioma

This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.

REC-2282

for Meningioma

This trial is testing a new drug called REC-2282 to see if it can help treat specific brain tumors in patients who haven't responded to other treatments. The study will check if the drug can slow down or stop the growth of these tumors.

More about Thomas Kaley, MD

Other Doctors you might be interested in

Frequently asked questions